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Quarterly Visits With Glycated
Hemoglobin Monitoring: The
Sweet Spot for Glycemic Control in
Youth With Type 1 Diabetes
OBJECTIVE
To evaluate the association between the frequency of visits and glycated hemo-
globin (GHb) measurements on glycemic control in youth with type 1 diabetes.
RESEARCH DESIGN AND METHODS
A retrospective longitudinal cohort study of 1,449 youth with type 1 diabetes
(mean age 11.4 years, 50% female, 74% Caucasian, 24%withMedicaid) followed at
five pediatric endocrinology clinics from the years 2008–2011 was conducted. By
hierarchical cluster analysis, three homogeneous groups of patients were gener-
ated: those with a relative increase in GHb (worsened [n = 237]), no change in GHb
(stable [n = 842]), and a decrease in GHb (improved [n = 370]) over the study
period. The number of visits and GHb measurements per year were compared
among the three groups by multinomial logistic regression analysis using one visit
or GHb test per year as a reference and controlling for patient demographic and
baseline characteristics.
RESULTS
Patients with quarterly visits were least likely to have worsened glycemic control
(odds ratio 0.33, P, 0.05) andweremost likely to have improved glycemic control
(3.48, P , 0.01). Patients with four GHb tests a year (0.53, P , 0.05) were least
likely to have worsened glycemic control.
CONCLUSIONS
Quarterly visits andGHb testing are associatedwith glycemic control in youthwith
type 1 diabetes.
Diabetes Care 2014;37:341–345 | DOI: 10.2337/dc13-0980
Optimal glycemic control is associated with a reduction in the risk for complications
associated with diabetes (1–3). However, glycemic control remains suboptimal in
many youth with type 1 diabetes (4–7). The American Diabetes Association
proposed guidelines recommending visits with a health care provider and
glycated hemoglobin (GHb) testing at least two times a year for patients with good
glycemic control and quarterly for patientswith poor glycemic control (8,9), presuming
that close monitoring improves management and reduces complications.
1Nemours Weight Management Division, Alfred I.
duPont Hospital for Children, Wilmington, DE
2Nemours Division of Bioinformatics, Alfred I.
duPont Hospital for Children, Wilmington, DE
3Nemours Office of Quality and Safety, Alfred I.
duPont Hospital for Children, Wilmington, DE
4Nemours Office of Quality and Safety, Nemours
Children’s Hospital, Orlando, FL
Corresponding author: Lloyd Neil Werk, lloyd.
werk@nemours.org.
Received 25 April 2013 and accepted 18
September 2013.
© 2014 by the American Diabetes Association.
See http://creativecommons.org/licenses/by-
nc-nd/3.0/ for details.
Thao-Ly Phan,1 Jobayer Hossain,2
Stephen Lawless,3 and Lloyd Neil Werk4
Diabetes Care Volume 37, February 2014 341
C
LIN
C
A
R
E/ED
U
C
A
TIO
N
/N
U
TR
ITIO
N
/P
SYC
H
O
SO
C
IA
L
Despite the perceived value of routinely
monitoring GHb, the importance of GHb
testing at regular intervals has not been
well described in youth and has been
documented in only one adult study
(10). Studies in adults have
demonstrated the important role of
frequent visits in achieving glycemic
control (11,12), a finding supported by
one study in youth with type 1 diabetes
that found improved glycemic control in
those who had three or four visits per
year compared with those who had only
one or two (13). The frequency of visits
and GHb testing is determined by
provider preference but can also be
influenced by patient treatment
adherence, with higher rates of
nonadherence described in patients of
lower socioeconomic status, single-
parent households, and minority race
(13–15).
Determination of the optimal number of
visits and GHb testing in youth with type
1 diabetes to optimize glycemic control
may inform the practice of cost-
effective medicine. Furthermore,
adoption of different management
schedules may be more effective for
patient subgroups according to baseline
characteristics. In the present study, we
examined the relationship between
frequency of visits and GHb testing on
glycemic control in youth with type 1
diabetes.
RESEARCH DESIGN AND METHODS
The dataset from a retrospective cohort
study was extracted from the electronic
medical record (EMR). This longitudinal
study used deidentified records
extending from July 2008 to June 2011
and was approved by the Nemours
Institutional Review Board.
Patients were included in the study if
they were seen at any of five Nemours
pediatric endocrinology clinics
(Jacksonville, Orlando, and Pensacola,
FL; Philadelphia, PA; and Wilmington,
DE) during the first two fiscal quarters of
2008 and had a previous diagnosis of
type 1 diabetes identified on their
problem list. Scheduled visits with an
endocrinology provider (visit) were
recorded in and extracted from the
EMR. No routine scheduling protocols
were used at any of the practices.
Patients were excluded from the study if
they had only one visit, had a single GHb
test, or were followed for ,1 year.
Demographics, including age, sex, race,
practice location, and insurance status,
were obtained from the EMR.
GHb Measurement
GHb measurements were obtained at
the discretion of the provider. Each site
was internally consistent, using the
same device to provide a point of care
(POC) GHb assay. The same type of POC
GHb device (Siemens DCA Vantage
Analyzer) was used at all sites. The
detection range with this device for the
GHb assay is 2.5–14% (4–130 mmol/
mol), with a reference range of 4.4–6.4%
(25–46 mmol/mol). GHb values .14%
were unable to be quantified and, thus,
were coded as 14% in the dataset. The
standard operating procedure at each
site was to collect blood samples for
POC testing at the time of the office visit,
but GHb from external laboratory
specimens were also included if
available. The DCA Vantage Analyzer has
acceptable precision (16).
Statistical Analysis
The number of visits and GHb tests per
year were calculated and served as the
primary independent variables. The
number of fiscal quarters in a year with
visits and GHb tests obtained were
calculated and served as secondary
independent variables. We used a
mixed-effects model (17) to
characterize the individual- and
population-level changes in GHb over
time and with visit frequency. Change
from baseline GHb was used as the
response variable, and patient
demographic variables, baseline GHb,
and time from study entry were used as
fixed-effects variables in the model. The
intercept and visit frequencies were
used as random effects in the model to
capture the pattern of individual-level
changes in GHb over visit frequencies.
A hierarchical cluster analysis of random
effects (17,18) was performed to group
patients by homogeneous patterns of
glycemic control. The cluster analysis
identified the following three distinct
and significantly different group
patterns of change in GHb per year (P,
0.001): a relative increase (worsened
glycemic control), no change (stable
glycemic control), or a decrease
(improved glycemic control) in GHb over
the study period. Study variables,
including demographics, baseline
characteristics, and the independent
variables of visit and GHb testing
frequency, were compared among the
three groups.
Quantitative variables are presented as
mean (SD). Categorical variables are
presented as frequencies and
percentages. Multivariable multinomial
logistic regression analyses were
performed to explore the association
of study variables with glycemic control
groups. The adjusted odds ratios (ORs)
with P values are presented in the text,
with CIs also presented in the tables.
Model assumptions were verified
before analyses. All tests were two
tailed at the 0.05 level of significance.
SAS (SAS Institute, Cary, NC) and SPSS
(IBM Corporation, Chicago, IL) statistical
software programs were used for the
analyses.
RESULTS
Categorization of Patients on the
Basis of Change in GHb
Mean GHb in the cohort remained
relatively stable over the study period,
increasing slightly from 8.3% (SD 1.5%)
(67 mmol/mol) during the initial year
of study to 8.5% (1.4%) (69 mmol/mol)
during the last year of study. Table 1
shows the GHb trends over the study
period for the three groups of glycemic
control generated by the hierarchical
cluster analysis: worsened (n = 237),
stable (n = 842), and improved
(n = 370).
Patient Characteristics
There were 1,449 patients included in
the study (Table 2). The mean age was
11.4 (SD 3.3) years. There were an equal
proportion of males and females. The
majority of patients were Caucasian
(74%) and had commercial insurance
(67%). Patients who were African
American (OR 1.78, P , 0.01), had
Medicaid insurance (1.51, P , 0.01), or
were older (F = 1.11, P , 0.001) were
more likely to have worsened glycemic
control (Table 2). Patients with higher
baseline GHb were more likely to
have improved glycemic control (F = 1.43,
P , 0.001).
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Relationship Between Glycemic
Control and Office Visit Frequency
On average, patients had 3.2 (SD 1.1,
range 1–11) visits per year and 2.9
(0.7) fiscal quarters with visits per
year. Table 3 compares groups on the
basis of visit frequency, with the
reference group being patients with
one visit or one fiscal quarter with
visits per year and adjusting for
demographic and baseline
characteristics. Patients with four
visits per year (OR 0.36, P , 0.05) or
quarterly visits (0.33, P , 0.05) were
least likely to have worsened glycemic
control. Patients with quarterly visits
were also most likely to have improved
glycemic control (3.48, P , 0.01). In
multivariable regression analysis, race
(P , 0.005), insurance status (P ,
0.01), and initial age (P , 0.05) had
significant effects on visit frequency.
Relationship Between Glycemic
Control and Frequency of GHb Testing
On average, patients had 3.0 (SD 1.0,
range 1–10) GHb tests per year and 2.8
(0.7) fiscal quarters in a year with a GHb
test. Table 3 compares groups on the
basis of GHb testing frequency, with
the reference group being patients
with one GHb test per year or one fiscal
quarter per year with a GHb obtained
and adjusting for demographic and
baseline characteristics. Patients with
four GHb tests per year were least
likely to have worsened glycemic
control (OR 0.53, P , 0.05), and
patients with more than five GHb tests
per year were least likely to have
improved glycemic control (0.28, P ,
0.01). In multivariable regression
analysis, race (P , 0.01), insurance
status (P , 0.05), and initial age (P ,
0.05) had significant effects on
frequency of GHb testing.
Characterization of Patients With
More Than Five Office Visits per Year
A small percentage (7.9%) of patients
had five or more visits per year (mean
5.7 [SD 1.3], range 5–11). These patients
were more likely to have a higher
baseline GHb (F = 1.15, P , 0.05), have
Medicaid (OR 2.13, P , 0.001), or be
non-Hispanic (2.94, P , 0.05) and were
less likely to have improved glycemic
control (0.31, P , 0.001).
Table 1—Mean patient GHb over time by glycemic control group
GHb
Glycemic control
Year All patients Worsened Stable Improved
2008
% 8.3 (0.03) 8.8 (0.07) 8.1 (0.03) 8.3 (0.06)
mmol/mol 66.8 (0.27) 72.8 (0.77) 64.8 (0.31) 67.6 (0.63)
n 1,449 237 842 370
2009
% 8.4 (0.02) 9.8 (0.06) 8.3 (0.02) 7.9 (0.04)
mmol/mol 68.5 (0.24) 83.6 (0.67) 66.8 (0.25) 62.3 (0.44)
n 1,419 230 832 357
2010
% 8.4 (0.02) 10.1 (0.06) 8.3 (0.02) 7.8 (0.04)
mmol/mol 68.8 (0.25) 86.9 (0.70) 67.2 (0.26) 61.2 (0.41)
n 1,359 213 798 348
2011
% 8.5 (0.03) 10.2 (0.10) 8.4 (0.04) 7.9 (0.06)
mmol/mol 69.9 (0.38) 88.1 (1.07) 68.2 (0.39) 63.1 (0.65)
n 1,094 160 649 285
Data are mean (SD) unless otherwise indicated.
Table 2—Comparison of glycemic control groups on the basis of patient characteristics
Glycemic control F or adjusted OR (CI) for glycemic control
All patients
(n = 1,449)
Improved
(n = 370)
Stable
(n = 842)
Worsened
(n = 237) Worsened†‡ Improved‡§
Baseline GHb, mean (SD) 0.93 1.43***
% 8.3 (1.5) 8.8 (1.8) 8.0 (1.3) 8.3 (1.4)
mmol/mol 66.8 (16.6) 73.1 (19.9) 64.1 (14.4) 66.7 (15.4)
Age (years), mean (SD) 11.4 (3.3) 11.0 (3.6) 11.4 (3.3) 12.2 (2.7) 1.11*** 0.93***
Sex
Male 726 (50.1) 174 (24.1) 424 (58.6) 125 (17.3) Reference Reference
Female 723 (49.9) 196 (27.0) 418 (57.6) 112 (15.4) 0.88 (0.66–1.17) 1.05 (0.82–1.35)
Race/ethnicity
Caucasian 1,076 (74.3) 265 (24.6) 653 (60.7) 158 (14.7) Reference Reference
African American 161 (11.1) 41 (25.5) 81 (50.3) 39 (24.2) 1.78** (1.17–2.72) 0.71 (0.47–1.01)
Hispanic 148 (10.2) 43 (29.1) 76 (51.4) 29 (19.6) 1.41 (0.89–2.23) 0.97 (0.65–1.45)
Other 64 (4.4) 21 (32.8) 32 (50) 11 (17.2) 1.34 (0.67–2.67) 1.18 (0.66–2.09)
Insurance
Commercial 972 (67.1) 238 (24.5) 594 (61.1) 140 (14.4) Reference Reference
Medicaid 346 (23.9) 104 (30.1) 169 (48.8) 73 (21.1) 1.51* (1.08–2.11) 0.91 (0.58–1.44)
Other 131 (9.0) 28 (21.4) 79 (60.3) 24 (18.3) 1.15 (0.70–1.87) 1.08 (0.80–1.46)
Data are mean (SD) or n (%) unless otherwise indicated. *P , 0.05. **P , 0.01. ***P , 0.001. †Compared with groups with stable or improved
glycemic control. ‡Controlling for remainder of patient characteristics. §Compared with group with stable or worsened glycemic control.
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CONCLUSIONS
Consistent with prior studies (14,15),
this longitudinal cohort study of 1,449
youth with type 1 diabetes supports the
importance of routine visits and GHb
testing in this population. The findings
suggest that quarterly visits and GHb
monitoring may prevent worsening
glycemic control in youth with type 1
diabetes. These findings were present
even when adjusting for factors known
to affect glycemic control and treatment
adherence, including race, insurance
status, age, and baseline GHb. It is likely
that patients with less frequent visits or
GHb testing may miss opportunities to
receive education, support, and changes
to treatment regimens to promote
glycemic control (11,19).
Patients with worsened glycemic
control over the study period had lower
baseline GHb than patients with stable
and improved glycemic control.
Although this may represent a
regression of GHb values to the mean,
the associations between visit and
laboratory frequency with glycemic
control were significant even after
adjusting for baseline GHb. We also
found that patients of African American
race, with Medicaid, or of older age
were more likely to have worsened
glycemic control, findings consistent
with other studies (13–15,19–22).
These subgroups had fewer visits and
GHb tests, which may explain their
increased likelihood for worsened
glycemic control.
A subgroup of patients required more
than four visits a year and demonstrated
worsened glycemic control. It is likely
that these patients represent a need for
more frequent follow-up and
monitoring because of their poor
glycemic control, as demonstrated by
their higher baseline GHb. Of note,
these patients were more likely to have
Medicaid, which may be a proxy for low
socioeconomic status and has been
associated with poor glycemic control in
prior studies (13–15,20,21).
Because this was a retrospective study
using primarily administrative data and
laboratory results previously recorded
in our EMR, several limitations should
be noted. We were unable to account
for certain factors that may have
influenced glycemic control, including
interventions other than visits with
endocrinology physicians and nurse
practitioners, duration of diabetes
diagnosis, type of insulin regimen used,
maturation (Tanner stage), and GHb
device used (whether with a POC device
or at an external laboratory). We also
were unable to account for certain
factors that may have influenced visit
frequency, such as provider preference,
which may have been influenced by
glycemic control, patient motivation
and adherence, and other
socioeconomic variables beyond
insurance status. Future studies should
examine the role of these factors on visit
and GHb testing frequency in addition to
glycemic control.
In summary, quarterly visits and GHb
testing are associated with glycemic
control in youth with type 1 diabetes.
Certain patient subgroups have less
frequent visits and GHb testing and may
require increased support to ensure
adherence to visit and GHb testing
recommendations.
Table 3—Comparison of glycemic control groups on the basis of visit and laboratory frequency
Glycemic control Adjusted OR (CI) for glycemic control
All patients Improved Stable Worsened Worsened†‡ Improved‡§
Visits per year
1 (n = 34) 34 (2.3) 11 (32.4) 13 (38.2) 10 (29.4) Reference Reference
2 (n = 214) 214 (14.8) 81 (37.9) 98 (45.8) 35 (16.4) 0.46 (0.20–1.07) 1.45 (0.65–3.26)
3 (n = 572) 527 (39.5) 150 (26.2) 323 (56.5) 99 (17.3) 0.51 (0.23–1.12) 0.87 (0.40–1.90)
4 (n = 515) 515 (35.5) 113 (21.9) 336 (65.2) 66 (12.8) 0.36 (0.16–0.81)* 0.75 (0.34–1.65)
$5 (n = 114) 114 (7.9) 15 (13.2) 72 (63.2) 27 (23.7) 0.71 (0.29–1.70) 0.33 (0.13–0.85)
Quarters per year with visits||
1 (n = 58) 58 (4.0) 16 (27.6) 27 (46.6) 15 (25.9) Reference Reference
2 (n = 300) 300 (20.7) 90 (30.0) 150 (50.0) 60 (20.0) 0.95 (0.37–1.91) 1.54 (0.70–3.39)
3 (n = 745) 745 (51.4) 188 (25.2) 440 (59) 117 (15.7) 0.56 (0.23–1.35) 2.32 (1.00–5.41)
4 (n = 346) 346 (23.9) 76 (22.0) 225 (65.0) 45 (13.0) 0.33 (0.12–0.90)* 3.48 (1.38–8.76)**
GHb per year
1 (n = 65) 65 (4.5) 20 (30.8) 29 (44.6) 16 (24.6) Reference Reference
2 (n = 309) 309 (21.3) 111 (35.9) 153 (49.5) 45 (14.6) 0.58 (0.30–1.12) 1.26 (0.68–2.31)
3 (n = 686) 686 (47.3) 157 (22.9) 412 (60.1) 117 (17.1) 0.74 (0.40–1.36) 0.69 (0.38–1.24)
4 (n = 301) 301 (20.8) 71 (23.6) 191 (63.5) 39 (13) 0.53 (0.27–1.03)* 0.79 (0.42–1.47)
$5 (n = 88) 88 (6.1) 10 (11.4) 55 (62.5) 23 (26.1) 0.96 (0.44–2.01) 0.28 (0.12–0.65)**
Quarters per year with GHb obtained¶
1 (n = 75) 75 (5.2) 21 (28) 37 (49.3) 17 (22.7) Reference Reference
2 (n = 366) 366 (25.3) 120 (32.3) 181 (49.5) 65 (17.8) 5.84 (0.61–55.81) 2.26 (0.25–20.73)
3 (n = 730) 750 (50.4) 166 (22.7) 441 (60.4) 123 (16.8) 2.21 (0.24–20.08) 4.74 (0.47–47.52)
4 (n = 278) 278 (19.2) 63 (22.7) 183 (65.8) 32 (11.5) 0.97 (0.11–8.75) 7.18 (0.68–76.47)
Data are n (%) unless otherwise indicated. *P, 0.05. **P, 0.01. †Compared with group with stable or improved glycemic control. ‡Controlling for
age, sex, race, insurance status, and baseline GHb. §Compared with group with stable or worsened glycemic control. ||OR also controlling for
absolute number of visits per year. ¶OR also controlling for absolute number of GHb tests per year.
344 Visit Frequency and Glycemic Control Diabetes Care Volume 37, February 2014
Acknowledgments. The authors thank Iman
Sharif, Nemours Division of General Pediatrics,
for assistance in editing the manuscript. The
authors also thank the Endocrinology Division of
Nemours, whose clinical practice and patient
population were featured in this study.
Duality of Interest. No potential conflicts of
interest relevant to this article were reported.
Author Contributions. T.-L.P. wrote the
manuscript. J.H. analyzed the data. S.L. and L.N.W.
researched data and edited the manuscript.
J.H. is the guarantor of this work and, as such,
had full access to all the data in the study and
takes responsibility for the integrity of the data
and the accuracy of the data analysis.
Prior Presentation. Parts of this study were
presented in abstract form as a poster
presentation at the Eastern Society for Pediatric
Research Annual Meeting, Philadelphia, PA,
30 March–1 April 2012.
References
1. The Diabetes Control and Complications
Trial Research Group. The effect of
intensive treatment of diabetes on the
development and progression of long-term
complications in insulin-dependent
diabetes mellitus. N Engl J Med 1993;329:
977–986
2. Morales A. A better future for children with
type 1 diabetes: review of the conclusions
from the Diabetes Control and
Complications Trial and the Epidemiology
of Diabetes Interventions and
Complications study. J Ark Med Soc 2009;
106:90–93
3. Genuth S. Insights from the diabetes
control and complications trial/
epidemiology of diabetes interventions and
complications study on the use of intensive
glycemic treatment to reduce the risk of
complications of type 1 diabetes. Endocr
Pract 2006;12(Suppl. 1):34–41
4. Hood KK, Peterson CM, Rohan JM, Drotar D.
Association between adherence and
glycemic control in pediatric type 1
diabetes: a meta-analysis. Pediatrics 2009;
124:e1171–e1179
5. Danne T, Mortensen HB, Hougaard P, et al.;
Hvidøre Study Group on Childhood
Diabetes. Persistent differences among
centers over 3 years in glycemic control and
hypoglycemia in a study of 3,805 children
and adolescents with type 1 diabetes from
the Hvidøre Study Group. Diabetes Care
2001;24:1342–1347
6. Cengiz E, Xing D, Wong JC, et al.; T1D
Exchange Clinic Network. Severe
hypoglycemia and diabetic ketoacidosis
among youth with type 1 diabetes in the
T1D Exchange Clinic Registry. Pediatr
Diabetes 2013;14:447–454
7. Kim H, Elmi A, Henderson CL, Cogen FR,
Kaplowitz PB. Characteristics of
children with type 1 diabetes and
persistent suboptimal glycemic control.
J Clin Res Pediatr Endocrinol 2012;4:
82–88
8. American Diabetes Association. Executive
summary: standards of medical care in
diabetesd2011. Diabetes Care 2011;34
(Suppl. 1):S4–S10
9. Silverstein J, Klingensmith G, Copeland K,
et al.; American Diabetes Association. Care
of children and adolescents with type 1
diabetes: a statement of the American
Diabetes Association. Diabetes Care 2005;
28:186–212
10. Larsen ML, Hørder M, Mogensen EF. Effect
of long-term monitoring of glycosylated
hemoglobin levels in insulin-dependent
diabetes mellitus. N Engl J Med 1990;323:
1021–1025
11. Hueston WJ. Does having a personal
physician improve quality of care in
diabetes? J Am Board Fam Med 2010;23:
82–87
12. O’Connor PJ, Desai J, RushWA, Cherney LM,
Solberg LI, Bishop DB. Is having a regular
provider of diabetes care related to
intensity of care and glycemic control?
J Fam Pract 1998;47:290–297
13. Kaufman FR, Halvorson M, Carpenter S.
Association between diabetes control and
visits to a multidisciplinary pediatric
diabetes clinic. Pediatrics 1999;103:948–
951
14. Jacobson AM, Hauser ST, Willett J,
Wolfsdorf JI, Herman L. Consequences of
irregular versus continuous medical follow-
up in children and adolescents with insulin-
dependent diabetes mellitus. J Pediatr
1997;131:727–733
15. Auslander WF, Thompson S, Dreitzer D,
White NH, Santiago JV. Disparity in
glycemic control and adherence between
African-American and Caucasian youths
with diabetes. Family and community
contexts. Diabetes Care 1997;20:1569–
1575
16. Lenters-Westra E, Slingerland RJ. Six of
eight hemoglobin A1c point-of-care
instruments do not meet the general
accepted analytical performance criteria.
Clin Chem 2010;56:44–52
17. Tan P-N, Steinbach M, Kumar V.
Introduction to Data Mining. Boston, MA,
Addison-Wesley, 2005
18. HossainMJ,Wysocki T, GongM, Gidding SS,
Bunnell TH. Evaluating the performance of
clustering using different inputs and
algorithms to group children based on
early childhood growth patterns. Available
from http://www.udel.edu/ASA/
sep2012_meeting.html. Presented at the
American Statistical Association Delaware
Chapter, 20 September 2012, at the
University of Delaware, Newark, Delaware
19. Borus JS, Laffel L. Adherence challenges in
the management of type 1 diabetes in
adolescents: prevention and intervention.
Curr Opin Pediatr 2010;22:405–411
20. Hassan K, Loar R, Anderson BJ, Heptulla RA.
The role of socioeconomic status,
depression, quality of life, and glycemic
control in type 1 diabetes mellitus. J Pediatr
2006;149:526–531
21. Zuijdwijk CS, Cuerden M, Mahmud FH.
Social determinants of health on glycemic
control in pediatric type 1 diabetes.
J Pediatr 2013;162:730–735
22. Hilliard ME, Wu YP, Rausch J, Dolan LM,
Hood KK. Predictors of deteriorations in
diabetes management and control in
adolescents with type 1 diabetes. J Adolesc
Health 2013;52:28–34
care.diabetesjournals.org Phan and Associates 345
